Aprea Therapeutics, a Phase 3 biotech developing targeted therapies for cancer, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Boston, MA-based company was founded in 2002 and plans to list on the Nasdaq under the symbol APRE. Aprea Therapeutics filed confidentially on July 12, 2019. J.P. Morgan, Morgan Stanley and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Cancer biotech Aprea Therapeutics files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.